SCHEMBL29985339

SCHEMBL29985339

[H]/N=C(\OC(C)(C)C)N(C(C)C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31524055 1.00
SCHEMBL2895286 0.84
SCHEMBL29149690 0.67 TSHR (0.30)
SCHEMBL12261426 0.65 HDAC6 (0.36)
SCHEMBL21811860 0.61
SCHEMBL23193949 0.60 NPSR1 (0.33)
SCHEMBL9825491 0.59 TSHR (0.33)
SCHEMBL22186495 0.58 KMT2A (0.33)
SCHEMBL21891538 0.57 PRKCA (0.34)
SCHEMBL22979290 0.57 CA12 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540267-B1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2026-04-15 EP disclosed
CN-118930560-A Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof 新锐思生物制药股份有限公司 2024-11-12 CN disclosed
EP-4346898-A1 METHODS FOR INHIBITING RAS Revolution Medicines, Inc. (US) 2024-04-10 EP disclosed
CN-117813307-A Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof 新锐思生物制药股份有限公司 2024-04-02 CN disclosed
US-20230406885-A1 CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2023-12-21 US disclosed
WO-2023196614-A1 METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS AXONIS THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
EP-4146660-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2023-03-15 EP disclosed
WO-2022251292-A1 METHODS FOR INHIBITING RAS Revolution Medicines, Inc. (US) 2022-12-01 WO disclosed